Cancer-Specific Mortality among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-center Study Using Propensity Scoring and Competing Risk Regression Analyses
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Studies comparing radical prostatectomy (RP) outcomes with those of radiotherapy with or without androgen deprivation therapy (RT±ADT) for prostate cancer (PCa) have yielded conflicting results. Therefore, we used propensity score-matched analysis and competing risk regression analysis to compare cancer-specific mortality (CSM) and other-cause mortality (OCM) between these two treatments. Materials and Methods The multi-center, Severance Urological Oncology Group registry was utilized to identify 3,028 patients with clinically localized or locally advanced PCa treated by RP (n=2,521) or RT±ADT (n=507) between 2000 and 2016. RT±ADT cases (n=339) were matched with an equal number of RP cases by propensity scoring based on age, preoperative prostate-specific antigen, clinical tumor stage, biopsy Gleason score, and Charlson Comorbidity Index (CCI). CSM and OCM were co-primary endpoints. Results Median follow-up was 65.0 months. Five-year overall survival rates for patients treated with RP and RT±ADT were 94.7% and 92.0%, respectively (p=0.105). Cumulative incidence estimates revealed comparable CSM rates following both treatments within all National Comprehensive Cancer Network risk groups. Gleason score ! 8 was associated with higher risk of CSM (p=0.009). OCM rates were comparable between both groups in the low- and intermediate-risk categories (p=0.354 and p=0.643, respectively). For high-risk patients, RT±ADT resulted in higher OCM rates than RP (p=0.011). Predictors of OCM were age ! 75 years (p=0.002) and CCI ! 2 (p < 0.001). Conclusion RP and RT±ADT provide comparable CSM outcomes in patients with localized or locally advanced PCa. The risk of OCM may be higher for older high-risk patients with significant comorbidities.
Abstract
Purpose Studies comparing radical prostatectomy (RP) outcomes with those of radiotherapy with or without androgen deprivation therapy (RT±ADT) for prostate cancer (PCa) have yielded conflicting results. Therefore, we used propensity score-matched analysis and competing risk regression analysis to compare cancer-specific mortality (CSM) and other-cause mortality (OCM) between these two treatments. Materials and Methods The multi-center, Severance Urological Oncology Group registry was utilized to identify 3,028 patients with clinically localized or locally advanced PCa treated by RP (n=2,521) or RT±ADT (n=507) between 2000 and 2016. RT±ADT cases (n=339) were matched with an equal number of RP cases by propensity scoring based on age, preoperative prostate-specific antigen, clinical tumor stage, biopsy Gleason score, and Charlson Comorbidity Index (CCI). CSM and OCM were co-primary endpoints. Results Median follow-up was 65.0 months. Five-year overall survival rates for patients treated with RP and RT±ADT were 94.7% and 92.0%, respectively (p=0.105). Cumulative incidence estimates revealed comparable CSM rates following both treatments within all National Comprehensive Cancer Network risk groups. Gleason score ! 8 was associated with higher risk of CSM (p=0.009). OCM rates were comparable between both groups in the low- and intermediate-risk categories (p=0.354 and p=0.643, respectively). For high-risk patients, RT±ADT resulted in higher OCM rates than RP (p=0.011). Predictors of OCM were age ! 75 years (p=0.002) and CCI ! 2 (p < 0.001). Conclusion RP and RT±ADT provide comparable CSM outcomes in patients with localized or locally advanced PCa. The risk of OCM may be higher for older high-risk patients with significant comorbidities.
참고문헌 (30)
- Heidenreich A, "EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intentupdate 2013", Eur Urol, 65, pp.124~137 (2014)[DOI]
- [URL]
- Paulson DF, "Radical surgery versus radiotherapy for adenocarcinoma of the prostate", J Urol, 128, pp.502~504 (1982)[DOI]
- Wallace K, "Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial", J Clin Oncol, 24, pp.4158~4162 (2006)[DOI]
- Merglen A, "Short- and long-term mortality with localized prostate cancer", Arch Intern Med, 167, pp.1944~1950 (2007)[DOI]
- Zelefsky MJ, "Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix", J Clin Oncol, 28, pp.1508~1513 (2010)[DOI]
- Albertsen PC, "13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort", J Urol, 177, pp.932~936 (2007)[DOI]
- Nepple KG, "Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity", Eur Urol, 64, pp.372~378 (2013)[DOI]
- Kibel AS, "Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era", J Urol, 187, pp.1259~1265 (2012)[DOI]
- Sooriakumaran P, "Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes", BMJ, 348, pp.g1502~ (2014)[DOI]
- Concato J, "Randomized, controlled trials, observational studies, and the hierarchy of research designs", N Engl J Med, 342, pp.1887~1892 (2000)[DOI]
- Donovan JL, "Development of a complex intervention improved randomization and informed consent in a randomized controlled trial", J Clin Epidemiol, 62, pp.29~36 (2009)[DOI]
- Cooperberg MR, "Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer", Cancer, 116, pp.5226~5234 (2010)[DOI]
- Penson DF, "An update on randomized clinical trials in localized and locoregional prostate cancer", Urol Oncol, 23, pp.280~288 (2005)[DOI]
- Rubin DB, "On principles for modeling propensity scores in medical research", Pharmacoepidemiol Drug Saf, 13, pp.855~857 (2004)[DOI]
- Boehmer D, "Guidelines for primary radiotherapy of patients with prostate cancer", Radiother Oncol, 79, pp.259~269 (2006)[DOI]
- Akakura K, "A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months", Jpn J Clin Oncol, 36, pp.789~793 (2006)[DOI]
- Johnston TJ, "Mortality among men with advanced prostate cancer excluded from the ProtecT Trial", Eur Urol, 71, pp.381~388 (2017)[DOI]
- Tewari A, "Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy: a propensity scoring approach", J Urol, 177, pp.911~915 (2007)[DOI]
- Lee BH, "Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence", Eur Urol, 67, pp.204~209 (2015)[DOI]
- Roach M 3rd, "Radical prostatectomy versus radiation and androgen deprivation therapy for clinically localized prostate cancer: how good is the evidence?", Int J Radiat Oncol Biol Phys, 93, pp.1064~1070 (2015)[DOI]
- Cooperberg MR, "National practice patterns and time trends in androgen ablation for localized prostate cancer", J Natl Cancer Inst, 95, pp.981~989 (2003)[DOI]
- Stephenson AJ, "Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition", J Clin Oncol, 24, pp.3973~3978 (2006)[DOI]
- D'Amico AV, "Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions", J Clin Oncol, 25, pp.2420~2425 (2007)[DOI]
- Keating NL, "Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer", J Natl Cancer Inst, 102, pp.39~46 (2010)[DOI]
- Nguyen PL, "Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a metaanalysis of randomized trials", JAMA, 306, pp.2359~2366 (2011)
- Efstathiou JA, "Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02", Eur Urol, 54, pp.816~823 (2008)[DOI]
- Moon DH, "What is the best way to radiate the prostate in 2016?", Urol Oncol, 35, pp.59~68 (2017)[DOI]
- Wilt TJ, "Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer", Ann Intern Med, 148, pp.435~448 (2008)[DOI]
- Zietman AL, "Comparison of conventional-dose vs highdose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial", JAMA, 294, pp.1233~1239 (2005)[DOI]